Tacrolimus Tablets

1. Product Introduction

Tacrolimus Tablets 1 mg are film-coated oral tablets containing anhydrous tacrolimus. Tacrolimus is a potent calcineurin inhibitor used in specialist immunosuppressive regimens to help prevent rejection following kidney, liver or heart transplantation, where approved for the specific product.

The supplied business description identifies Healthy Life Pharma Pvt. Ltd. as manufacturer and Healthy Inc as exporter. The manufacturing licence, WHO-GMP certification, product registration and export eligibility should be verified before publication. The submitted composition confirms a 1 mg film-coated tablet only; capsules, prolonged-release variants and other strengths are not confirmed.

2. Product Specifications

3. Manufacturing Technology

Tacrolimus has a narrow therapeutic index and low aqueous solubility, so formulation development requires careful control of content uniformity, dissolution, stability and bioavailability. Appropriate personnel protection and cross-contamination controls are important when handling potent immunosuppressants.

Specific claims about high-shear granulation, solid dispersion, isolators, dedicated facilities, release technology and packaging methods must be supported by the manufacturer’s validated process and approved product dossier. A 1 mg film-coated tablet should not be assumed to be interchangeable with an immediate-release capsule or prolonged-release formulation.

4. Quality Assurance

Relevant quality testing may include identity, assay, uniformity of dosage units, dissolution, impurities, stability and packaging integrity under the applicable approved specifications. For this narrow-therapeutic-index medicine, pharmacokinetic/bioequivalence evidence and the registered release characteristics are especially important. Numerical acceptance limits and equivalence claims require product-specific documentation.

5. Therapeutic Uses and Mechanism

Tacrolimus binds FKBP-12 and inhibits calcineurin-dependent T-cell activation, reducing immune responses that may otherwise damage a transplanted organ. It is used as part of combination immunosuppressive treatment for prevention of rejection after kidney, liver and heart transplantation, subject to the approved indication for the exact formulation and country.

Important: Tacrolimus is not a general-purpose “generic drug” category; its therapeutic class is immunosuppressant / calcineurin inhibitor. Its use and any treatment of rejection episodes must be directed by a transplant specialist.

6. Export and Regulatory Support

For B2B supply, request the applicable manufacturing licence, product registration details, batch Certificate of Analysis, stability data, approved artwork, pack specification and any available CTD/ACTD or bioequivalence documents. WHO-GMP, COPP, Free Sale Certificate and destination-market permissions must be confirmed for the relevant facility and product. Temperature requirements and logistics must follow validated product-specific shipping conditions.

7. Frequently Asked Questions

Q: What composition is confirmed?
A: Each film-coated tablet contains anhydrous tacrolimus 1 mg.

Q: Can a tacrolimus tablet be substituted for a capsule or another release formulation?
A: No automatic substitution should be made. Tacrolimus formulations may have different pharmacokinetics; any switch needs specialist oversight and therapeutic drug monitoring.

Q: Why are blood tests important?
A: Tacrolimus blood concentrations help clinicians balance rejection risk against toxicity, alongside kidney function, potassium, glucose and other monitoring.

8. Dosage and Administration

Specialist prescription only: The dose and dosing frequency depend on the exact approved formulation, transplant type, time since transplantation, interacting medicines, patient characteristics and measured whole-blood trough concentrations. Do not apply capsule or prolonged-release dosing instructions to this film-coated tablet without confirming its registered release profile.

Take exactly as prescribed, consistently with respect to food according to the approved label. Do not change brands, formulations, doses or schedules independently; missed-dose instructions must come from the specific product leaflet or transplant team.

9. Side Effects and Precautions

Major risks: serious infections and malignancies (including lymphoma and skin cancer) due to immunosuppression; nephrotoxicity, neurotoxicity, high potassium, high blood pressure and post-transplant diabetes. Tacrolimus can interact significantly with CYP3A inhibitors and inducers, including certain antifungals, antibiotics and anticonvulsants. Grapefruit can increase exposure.

Close monitoring of tacrolimus trough concentrations, renal function, electrolytes and glucose is essential. Pregnancy, vaccination, infection symptoms and all new medicines or supplements should be discussed promptly with the transplant team. Never discontinue suddenly without medical advice.

10. Storage Instructions

Keep tablets in their original packaging and follow the approved label for temperature, humidity and light protection. The supplied general claim of storage below 25°C must be checked against the exact registered formulation. Keep out of reach of children and do not use after expiry.